logo

For the Inventor, By the Inventor

Redwood City, CA, United States of America

Genelabs Technologies, Inc.


USPTO Granted Patents = 72

% Expired Patents = 27.8


Forward Citations = 1,190

Loading Chart...
Loading Chart...

73 inventors (with patents filed for the assignee):

goldMedal Kirk E Fry (19 out of 39 patents)

silverMedal Gregory R Reyes (18 out of 27 patents)

bronzeMedal Christopher Don Roberts (17 out of 22 patents)

4.  Jungsuh P Kim (12 out of 13 patents)

5.  Cynthia A Edwards (12 out of 12 patents)

6.  Charles Cantor (11 out of 101 patents)

7.  Natalia Dyatkina (11 out of 23 patents)

8.  Beth M Andrews (11 out of 11 patents)

9.  Jesse Daniel Keicher (10 out of 13 patents)

10.  Albert W Tam (10 out of 14 patents)

11.  Patrice O Yarbough (8 out of 11 patents)

12.  Kenneth G Hadlock (6 out of 12 patents)

13.  Dong-Fang Shi (6 out of 8 patents)

14.  Daniel W Bradley (6 out of 11 patents)

15.  Lisa M Turin (6 out of 6 patents)


Core Competencies:
Nucleoside Derivatives
Viral Infections
Antiviral Compounds
DNA-Binding Molecules
Hepatitis C
Bone Mineral Density
Antifungal Activity
Antibacterial Agents
Gene Expression
Molecular Cloning
HTLV
Peptide Antigens

72 patents:

1. 7612034 - Treatment of subnormal bone mineral density (2009-11-03),
2. 7511145 - Bicyclic heteroaryl derivatives (2009-03-31),
3. 7432248 - Nucleoside derivatives for treating Hepatitis C virus infection (2008-10-07),
4. 7425547 - Nucleoside derivatives for treating hepatitis C virus infection (2008-09-16),
5. 7414031 - 5-nitro-nucleoside compounds for treating viral infections (2008-08-19),
6. 7405204 - Nucleoside compounds for treating viral infections (2008-07-29),
7. 7304085 - Nitrogen-containing heteroaryl derivatives (2007-12-04),
8. 7244713 - Nucleoside compounds for treating viral infections (2007-07-17),
9. 7202223 - Nucleoside compounds for treating viral infections (2007-04-10),
10. 7189506 - DNA binding compound-mediated molecular switch system (2007-03-13),
11. 7169918 - [object Object] (2007-01-30),
12. 7157434 - Nucleoside compounds for treating viral infections (2007-01-02),
13. 7151089 - Nucleoside compounds for treating viral infections (2006-12-19),
14. 7144868 - Nucleoside compounds for treating viral infections (2006-12-05),
15. 7141680 - Aromatic compounds possessing antifungal or antibacterial activity (2006-11-28),
Genelabs Technologies, Inc. is a biotechnology company focused on developing innovative solutions for the diagnosis and treatment of infectious diseases. With a diverse portfolio of patented technologies, Genelabs aims to improve patient outcomes and advance the fields of molecular diagnostics and therapeutics. The company's expertise lies in the development of novel diagnostic tests and potential drug candidates for diseases such as HIV, hepatitis, and respiratory infections.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Genelabs Technologies, Inc.
72 Patents

#31 in Redwood City, CA

#1,204 in California

#5,099 in US

#10,377 in the World

Redwood City, CA (US)
Redwood City, CA, United States of America

Genelabs Technologies, Inc.

Forward Citations = 1,190

73 inventors:

goldMedal Kirk E Fry (19 out of 39 patents)

silverMedal Gregory R Reyes (18 out of 27 patents)

bronzeMedal Christopher Don Roberts (17 out of 22 patents)

4.  Jungsuh P Kim (12 out of 13 patents)

5.  Cynthia A Edwards (12 out of 12 patents)

Please report any incorrect information to [email protected]
Loading…